JP2024514293A - 前立腺がんの診断方法 - Google Patents

前立腺がんの診断方法 Download PDF

Info

Publication number
JP2024514293A
JP2024514293A JP2023560269A JP2023560269A JP2024514293A JP 2024514293 A JP2024514293 A JP 2024514293A JP 2023560269 A JP2023560269 A JP 2023560269A JP 2023560269 A JP2023560269 A JP 2023560269A JP 2024514293 A JP2024514293 A JP 2024514293A
Authority
JP
Japan
Prior art keywords
psma
pet
radioligand
group
contrast agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514293A5 (cg-RX-API-DMAC7.html
Inventor
カタファウ,アナ
ピエッラ,エリザベト パレラ
へ,ベイレイ
クパメガン,ユーロージ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024514293A publication Critical patent/JP2024514293A/ja
Publication of JP2024514293A5 publication Critical patent/JP2024514293A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2023560269A 2021-04-02 2022-04-01 前立腺がんの診断方法 Pending JP2024514293A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305432 2021-04-02
EP21305432.3 2021-04-02
PCT/EP2022/058754 WO2022207906A1 (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer

Publications (2)

Publication Number Publication Date
JP2024514293A true JP2024514293A (ja) 2024-04-01
JP2024514293A5 JP2024514293A5 (cg-RX-API-DMAC7.html) 2025-04-10

Family

ID=75588163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560269A Pending JP2024514293A (ja) 2021-04-02 2022-04-01 前立腺がんの診断方法

Country Status (9)

Country Link
US (1) US20240181092A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313175A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514293A (cg-RX-API-DMAC7.html)
KR (1) KR20230165761A (cg-RX-API-DMAC7.html)
CN (1) CN117120100A (cg-RX-API-DMAC7.html)
CA (1) CA3215723A1 (cg-RX-API-DMAC7.html)
IL (1) IL307381A (cg-RX-API-DMAC7.html)
TW (1) TW202304531A (cg-RX-API-DMAC7.html)
WO (1) WO2022207906A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN120897762A (zh) * 2023-04-12 2025-11-04 康奈尔大学 用于治疗癌症的放射治疗缀合物
WO2026027442A1 (en) 2024-08-01 2026-02-05 Novartis Ag Synthesis of a precursor of radiopharmaceutical products

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143736A1 (en) * 2013-03-15 2014-09-18 Cancer Targeted Technology Llc 18f-labeled psma-targeted pet imaging agents
JP2020528461A (ja) * 2017-07-28 2020-09-24 テクニシェ ユニバーシタット ミュンヘン デュアルモードの放射性トレーサーおよび療法剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143736A1 (en) * 2013-03-15 2014-09-18 Cancer Targeted Technology Llc 18f-labeled psma-targeted pet imaging agents
JP2020528461A (ja) * 2017-07-28 2020-09-24 テクニシェ ユニバーシタット ミュンヘン デュアルモードの放射性トレーサーおよび療法剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF NUCLEAR MEDICINE, vol. vol. 58 (suppl. 1), JPN6026011215, May 2017 (2017-05-01), pages 733, ISSN: 0005822573 *
JOURNAL OF NUCLEAR MEDICINE, vol. vol. 60(7), JPN6026011216, 21 November 2018 (2018-11-21), pages 910 - 916, ISSN: 0005822574 *

Also Published As

Publication number Publication date
TW202304531A (zh) 2023-02-01
CN117120100A (zh) 2023-11-24
WO2022207906A1 (en) 2022-10-06
IL307381A (en) 2023-11-01
KR20230165761A (ko) 2023-12-05
CA3215723A1 (en) 2022-10-06
EP4313175A1 (en) 2024-02-07
US20240181092A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
Lohrmann et al. Retooling a blood-based biomarker: phase I assessment of the high-affinity CA19-9 antibody HuMab-5B1 for immuno-PET imaging of pancreatic cancer
EP4313175A1 (en) Diagnostic methods of prostate cancer
Granov et al. Positron emission tomography
Sinnes et al. Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga] Ga-DATA-TOC
US20250025584A1 (en) Radiopharmaceutical treatment methods and use
US20250269073A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
Wu et al. First-in-human evaluation of [211At] YF2 in patients with metastatic castration-resistant prostate cancer
Dietlein et al. A novel 18F-labeled PSMA ligand for PET/CT imaging of prostate cancer patients: First-in-man observational study and clinical experience with 18F-JK-PSMA-7 during the first year of application
AU2018381046B2 (en) Radiolabeled progastrin in cancer diagnosis
Baum et al. Third theranostics world congress on gallium-68 and PRRT: abstracts
Rudd Looking backward to move forward: A chemist’s perspective on the future of radiopharmaceuticals
O'Brien et al. Managing a high-specific-activity iobenguane therapy clinic: from operations to reimbursement
US20250032651A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
US20240042067A1 (en) [177lu] lutetium-psma i&t composition, kit, method of making, and method of using thereof
Lucignani Non-standard PET radionuclides: time to get ready for new clinical PET strategies
Eckelman Review of new clinical applications of radiometal labeled radiopharmaceuticals
Elison et al. ANZSNM ASM 2021 POSTER PRESENTATIONS
PART growth factor (anti-VEGF), antiepidermal growth
Bailey Advancing targeting radiopharmaceuticals for theranostic applications
US20160193372A1 (en) Methods of identifying surrogate imaging agents for alpha emitter radiopharmaceuticals and their use in treatment of disease
Rose et al. Imaging with radionuclides
Bhusari et al. Lu-177-Herceptin: A Potential Radioimmunoconjugate for Treatment of HER2 Metastatic Breast Cancer
Lam Translation and Development of Molecular Imaging Probes for Detecting Response of Breast Cancer to Trastuzumab
Witkowska-Patena et al. 18F-PSMA-1007-a breakthrough in PET/CT prostate cancer imaging? A systematic review
Györke et al. Sapital standardisation of RCBF-SPECT in early dementia patients and healthy control subjects

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260604